Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

Cancer Research

Volumn 64, Issue 10, 2004, Pages 3668-3678

  Zeytin, Hasan E ^a   Patel, Arti C ^a   Rogers, Connie J ^a   Canter, Daniel ^a   Hursting, Stephen D ^a   Schlom, Jeffrey ^a   Greiner, John W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Lab of Tumor Immunology and Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CONCANAVALIN A; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROSTAGLANDIN E2; VIRUS VACCINE;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BREEDING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON POLYPOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; EOSINOPHILIA; EVIDENCE BASED MEDICINE; FEMALE; GENE EXPRESSION; GENE MUTATION; IMMUNE RESPONSE; IMMUNOSTIMULATION; KNOCKOUT MOUSE; LONG TERM CARE; MALE; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; POXVIRUS; PRECANCER; PRIORITY JOURNAL; PROGENY; PROSTAGLANDIN BLOOD LEVEL; PROTEIN TARGETING; RECOMBINANT DNA TECHNOLOGY; SPLEEN; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIET; EPITOPES; FEMALE; HUMANS; ISOENZYMES; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POXVIRIDAE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; T-LYMPHOCYTES; TRANSGENES;

EID: 2442686929     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3878     Document Type: Article

References (63)

1. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthetase (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
2. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89: 3917-21.
3. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbal ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthetase/cyclooxygenase homologue. J Biol Chem 1991; 266:12866-72.
4. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-72.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
6. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
7. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Eng J Med 2003;348:883-90.
8. Baron JA, Cole BF, Sandler RS, et al. randomized trial of aspirin to prevent colorectal adenomas. N Eng J Med 2003;348:891-9.
9. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641-5.
10. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Eng J Med 1999;340:1888-99.
11. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Invest Drugs 1999;8:1623-38.
12. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
13. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenesis and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
14. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87: 803-9.
15. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.
16. 716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
17. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a preventative and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
18. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
19. Guadagni F, Roselli M, Cosimelli M, et al. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation. Int J Cancer 1997;72: 949-54.
20. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-62.
21. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Lab Clin Anal 1991;5:344-66.
22. Eades-Perner A-M, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169-76.
23. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998; 58:1469-77.
24. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner J. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83.
25. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14.
26. Mizobata S, Tompkins K, Simpson JF, Shyr Y, Primus FP. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 2000;49:285-95.
27. Niethammer AG, Primus FJ, Xiang R, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 2001;20:421-9.
28. Xiang R, Primus FJ, Ruehlmann JM, et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001;167:4560-5.
29. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen (CEA) demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002;62:6944-52.
30. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332-7.
31. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000; 6:2219-28.
32. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73.
33. Iniguez MA, Punzon C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999;163:111-9.
34. Rivero M, Santiago B, Galindo M, Brehmer MT, Pablos JL. Cyclooxygenase-2 inhibition lacks immunomodulatory effects on T cells. Clin. and Exp Rheumatol 2002;20:379-85.
35. Langenbach R, Loftin C, Lee C, Tiano H. Cyclooxygenase knockout mice. Models for elucidating isoform-specific functions. Biochem Pharmacol 1999;58:1237-46.
36. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59: 5800-7.
37. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505.
38. Muraro R, Wunderlich D, Thor A, et al. Definition of monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinoma versus normal adult tissues. Cancer Res 1985;45:5769-80.
39. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-inducible carcinoembryonic antigen (CEA) CD8+ T-cell epitope which mediates tumor killing in CEA transgenic mice. Cancer Res 2002;62:5058-64.
40. Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods: A Comparison to Methods in Enzymol 1997;12:117-23.
41. + T cells in primary and secondary influenza pneumonia. Immunity 1998;8:683-91.
42. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
43. Su L-K, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene. Science 1992;256:668-70.
44. Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992;152:1521-4.
45. Takahashi Y, Roman C, Chemtob S, Tse MM, Lin E, Heymann MA, Clyman RI. Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol Regulatory Integrative Comp Physiol 2000;278:R1496-505.
46. Iniguez MA, Matinez-Martinez S, Punzon C, Redondo JM, Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000;275:23627-35.
47. Carey MA, Germolec DR, Bradbury A, et al. Accentuated T helper type 2 airway response after allergen challenge in cyclooxygenase-1 -/- but not cyclooxygenase-2 -/- mice. Am J Respir Crit Care Med 2003;167:1509-15.
48. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001;7:1048-51.
49. Hsu AL, Ching T-T, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
50. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
51. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
52. Paulsen JE, Namork E, Steffensen I-L, Eide TJ, Alexander J. Identification and quantification of aberrant crypt foci in the colon of Min mice - A murine model of familial adenomatous polyposis. Scand J Gastroenterol 2000;35:534-9.
53. Takeda H, Sonoshita M, Oshima H, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003;63:4872-7.
54. Finke J, Ferrone S, Frey A, Mufson A, Ocha A. Where have all the T cells gone? Mechanisms of immune evasion by tumor. Immunol Today 1999;20:158-60.
55. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003;9: 1837-49.
56. Gilboa, E. The risk of autoimmunity associated with tumor immunotherapy. Nature Immun 2001;2:789-92.
57. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
58. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. J Am Med Assoc 1999;282:1254-7.
59. Saukkonen K, Nieminen O, van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31.
60. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
61. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung carcinoma. Clin Cancer Res 1999;5: 1001-5.
62. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
63. Chan G, Boyle JO, Yang EK, et al. Cyclooxygesase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4.